<- Go Home

Bioventix PLC

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

Market Cap

GBP 148.9M

Volume

5.6K

Cash and Equivalents

GBP 5.1M

EBITDA

GBP 10.6M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

GBP 12.4M

Profit Margin

90.95%

52 Week High

GBP 45.80

52 Week Low

GBP 22.00

Dividend

5.44%

Price / Book Value

13.19

Price / Earnings

19.24

Price / Tangible Book Value

13.19

Enterprise Value

GBP 143.8M

Enterprise Value / EBITDA

13.57

Operating Income

GBP 10.5M

Return on Equity

69.08%

Return on Assets

50.09

Cash and Short Term Investments

GBP 5.1M

Debt

N/A

Equity

GBP 11.3M

Revenue

GBP 13.7M

Unlevered FCF

GBP 6.3M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches